[go: up one dir, main page]

NO20075142L - krystallformer av asenapinmaleat - Google Patents

krystallformer av asenapinmaleat

Info

Publication number
NO20075142L
NO20075142L NO20075142A NO20075142A NO20075142L NO 20075142 L NO20075142 L NO 20075142L NO 20075142 A NO20075142 A NO 20075142A NO 20075142 A NO20075142 A NO 20075142A NO 20075142 L NO20075142 L NO 20075142L
Authority
NO
Norway
Prior art keywords
crystal forms
asenapine maleate
crystal form
ortho
rhombic
Prior art date
Application number
NO20075142A
Other languages
English (en)
Other versions
NO340520B1 (no
Inventor
Gerhardus Johannes Heeres
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20075142(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of NO20075142L publication Critical patent/NO20075142L/no
Publication of NO340520B1 publication Critical patent/NO340520B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Oppfinnelsen angår en orto-rombisk krystallform av forbindelsen trans-5-klor-2,3,3a,12b-tetrahydro-2-metyl-1H-dibenz[2,3:6,7]oksepino[4,5-c]pyrrol(Z)-2-butendioat, metoder for fremstilling av denne krystallformen, og farmasøytiske preparater omfattende en orto-rombisk krystallform. ?? ?? ?? ?? 1
NO20075142A 2005-04-07 2007-10-10 Krystallform av asenapinmaleat, fremgangsmåte for fremstilling av slike, farmasøytiske sammensetninger omfattende slike samt anvendelse av slike for behandling av sykdom NO340520B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102969 2005-04-14
PCT/EP2006/061408 WO2006106135A1 (en) 2005-04-07 2006-04-06 Crystal form of asenapine maleate

Publications (2)

Publication Number Publication Date
NO20075142L true NO20075142L (no) 2007-11-05
NO340520B1 NO340520B1 (no) 2017-05-02

Family

ID=36617328

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075142A NO340520B1 (no) 2005-04-07 2007-10-10 Krystallform av asenapinmaleat, fremgangsmåte for fremstilling av slike, farmasøytiske sammensetninger omfattende slike samt anvendelse av slike for behandling av sykdom

Country Status (31)

Country Link
EP (2) EP1917267B1 (no)
JP (1) JP5058151B2 (no)
KR (1) KR101422843B1 (no)
AR (1) AR056306A1 (no)
AT (2) ATE418556T1 (no)
AU (1) AU2006231617B2 (no)
BR (1) BRPI0609741A8 (no)
CA (1) CA2603509C (no)
CY (2) CY1106902T1 (no)
DE (2) DE602006004463D1 (no)
DK (2) DK1710245T3 (no)
DO (1) DOP2006000082A (no)
ES (2) ES2318742T3 (no)
GT (1) GT200600135A (no)
HN (1) HN2006014095A (no)
HR (1) HRP20070429T3 (no)
IL (1) IL186355A (no)
MX (1) MX2007012445A (no)
MY (1) MY137969A (no)
NO (1) NO340520B1 (no)
NZ (1) NZ562124A (no)
PE (1) PE20061311A1 (no)
PL (2) PL1710245T3 (no)
PT (2) PT1917267E (no)
RS (1) RS50532B (no)
RU (1) RU2405786C2 (no)
SI (2) SI1917267T1 (no)
SV (1) SV2006002473A (no)
TW (1) TWI364423B (no)
UY (1) UY29459A1 (no)
WO (1) WO2006106135A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078024A1 (en) * 2006-10-06 2009-07-15 N.V. Organon Amorphous asenapine and processes for preparing same
CA2766291C (en) * 2009-06-24 2016-06-21 Msd Oss B.V. Injectable formulations containing asenapine and method of treatment using same
US8779161B2 (en) 2010-06-18 2014-07-15 Dr. Reddy's Laboratories Limited Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
EP2709615A1 (en) 2011-05-18 2014-03-26 Laboratorios Lesvi, S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
CN104487071B (zh) * 2012-07-26 2017-06-13 久光制药株式会社 贴附剂
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
WO2014090386A1 (en) 2012-12-11 2014-06-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
US10786520B2 (en) 2015-09-02 2020-09-29 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2019243452A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
DE69502939T2 (de) * 1994-03-02 1998-10-22 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
CY1108742T1 (el) 2014-04-09
CY1106902T1 (el) 2012-09-26
TW200722428A (en) 2007-06-16
EP1710245B1 (en) 2007-08-22
CA2603509C (en) 2013-12-03
TWI364423B (en) 2012-05-21
DE602006004463D1 (de) 2009-02-05
PT1710245E (pt) 2007-10-03
PE20061311A1 (es) 2007-02-09
MY137969A (en) 2009-04-30
IL186355A (en) 2016-05-31
ES2318742T3 (es) 2009-05-01
DOP2006000082A (es) 2006-11-30
MX2007012445A (es) 2007-11-07
RU2405786C2 (ru) 2010-12-10
PT1917267E (pt) 2009-02-04
UY29459A1 (es) 2006-11-30
KR20080005253A (ko) 2008-01-10
AR056306A1 (es) 2007-10-03
DK1917267T3 (da) 2009-04-14
ES2293626T3 (es) 2008-03-16
BRPI0609741A2 (pt) 2010-04-27
EP1710245A1 (en) 2006-10-11
DK1710245T3 (da) 2007-12-03
PL1710245T3 (pl) 2008-01-31
NO340520B1 (no) 2017-05-02
SI1710245T1 (sl) 2007-12-31
CA2603509A1 (en) 2006-10-12
SV2006002473A (es) 2009-11-24
WO2006106135A1 (en) 2006-10-12
DE602006000080T2 (de) 2008-05-15
AU2006231617A1 (en) 2006-10-12
RS50532B (sr) 2010-05-07
EP1917267B1 (en) 2008-12-24
IL186355A0 (en) 2008-01-20
BRPI0609741A8 (pt) 2018-03-13
KR101422843B1 (ko) 2014-07-24
AU2006231617B2 (en) 2010-06-03
JP5058151B2 (ja) 2012-10-24
GT200600135A (es) 2006-11-07
SI1917267T1 (sl) 2009-04-30
EP1917267A1 (en) 2008-05-07
HN2006014095A (es) 2010-08-19
HRP20070429T3 (en) 2007-11-30
NZ562124A (en) 2010-07-30
JP2008534656A (ja) 2008-08-28
ATE418556T1 (de) 2009-01-15
ATE370954T1 (de) 2007-09-15
PL1917267T3 (pl) 2009-06-30
RU2007141198A (ru) 2009-05-20
DE602006000080D1 (de) 2007-10-04

Similar Documents

Publication Publication Date Title
NO20075142L (no) krystallformer av asenapinmaleat
UA93044C2 (en) urn:schemas-microsoft-com:office:smarttagsCRYSTALFORM OF ASENAPINE MALEATE
WO2006050161A3 (en) Therapeutic furopyrimidines and thienopyrimidines
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
MX2007005221A (es) Formas cristalinas de ascomicina y preparacion de ellas.
WO2004043912A3 (en) Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
NO20071050L (no) Rapamycin-polymorf II og anvendelser derav
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2005037198A3 (en) Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors
IL172357A0 (en) Method for the production of substituted 3-aryl-butyl amine compounds
TW200621721A (en) Methods of preparing indazole compounds
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
NO20070550L (no) Fremgangsmate for fremstilling av pyrrolotriazinforbindelser
WO2005009347A3 (en) 7-substituted camptothecin and camptothecin analogs and methods for preparing same
IL175634A0 (en) Methods of preparing olanzapine
WO2006075139A3 (en) Novel process for the preparation of substituted indoles
EA200501829A1 (ru) Способ получения непептидных замещённых спиробензоазепиновых производных
IL173582A0 (en) A process for the preparation of phenyltetrazole derivatives
WO2006093719A8 (en) An efficient and stereoselective process for large scale synthesis of 3-(r)-3- (2,3-dihydrobenzofuran-5-yl)-1,2,3,4- tetrahydropyrrolo{3,4-b}quinolin-9-one
WO2007029082A3 (en) An improved fermentation process for preparing ascomycin
NO20053829D0 (no) Fremgangsmate og intermediater for fremstilling av olanzapin.
WO2006047507A3 (en) Phosphonate substituted kinase inhibitors
WO2007079929A3 (de) Substituierte tricyclische piperidon-derivate